CD8+ T cells are recognized as a population with antitumor effects, while CD4+ T cells have the advantage of enhancing the recruitment and effector functions of tumor-specific CD8+ T cells and activating natural killer cells in tumors, which has prompted investigators to screen for TSTs based on both subpopulations combined and individually (Figure 1). This evidence concerns the gene CD8A and neoplasm.